摘要
目的探讨依托泊苷胶囊联合沙利度胺治疗化疗耐药或无法耐受化疗的晚期软组织肉瘤患者的临床疗效。方法选取2017年3月至2018年1月间中国医学科学院北京协和医学院肿瘤医院收治的12例Ⅳ期软组织肉瘤患者,其中11例患者既往接受多柔比星联合异环磷酰胺化疗并取得疾病缓解或稳定,接受依托泊苷胶囊联合沙利度胺治疗。对其疗效和安全性进行回顾性分析。结果 12例患者完全缓解0例,部分缓解2例,稳定4例,进展6例。疾病控制率为50. 0%。中位无进展生存时间为4. 4个月。主要不良反应包括恶心呕吐3例,白细胞减少2例,皮疹2例,嗜睡2例,头晕1例,均为Ⅰ-Ⅱ度。结论依托泊苷胶囊联合沙利度胺治疗晚期软组织肉瘤有一定疗效,不良反应较轻,可提高患者生活质量。
Objective To observe safety and preliminary efficacy of combination therapy with etoposide capsule plus thalidomide for resistant or chemotherapy intolerant advanced soft tissue sarcoma.Methods Twelve patients with pathologically confirmed stage IV soft tissue sarcoma who were treated at Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College from March 2017 to January 2018 were selected. Among them 11 patients who had received reviously combination chemotherapy with doxorubicin and Ifosfamide and achieved remission or stable disease were given etoposide capsule plus thalidomide. Safety and efficacy were analyzed. Results Among the twelve patients enrolled,complete reponsed( CR) was not found. Partial reponse was achieved( PR) in two patients. Stable disease( SD) was achieved in four patients and progressive disease( PD) was found in six patients. The disease control rate( DCR) was 50%. Median progression-free survival( PFS) was 4. 4 months. Major adverse reactions included with nausea and vomiting in 3 patients,leukopenia in 2 patients,skin rash in 2 patients,drowsiness in 2 patients and dizziness in 1 patient. All the adverse reactions were grade Ⅰ toⅡ.Conclusion Etoposide capsule plus thalidomide have certain therapeutic benefit in patients with advanced soft tissue sarcoma. Adverse events are mild,and patients’ quality of life can be improved.
作者
左立杰
刘维丽
李蕊
赵文成
刘铮
依荷芭丽.迟
ZUO Li-jie;LIU Wei-li;LI Rui;ZHAO Wen-cheng;LIU Zheng;YIHEBALI Chi(Department of Medical Oncology,National Cancer Center,Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Beijing Chaoyang District Sanhuan Tumor Hospital,Beijing 100122,China)
出处
《中国肿瘤临床与康复》
2018年第12期1427-1430,共4页
Chinese Journal of Clinical Oncology and Rehabilitation
